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Intercellular communication is one of the most important factors involved in the maintenance of tissue homeo-
stasis. The alteration of intercellular interaction correlates with a lot of human diseases including canceroge-
nesis. There are several types of such interconnection. First of all, it is a direct cell-cell contact, as it takes place in
epithelium. The disturbance of this communication is expressed as a loss of cell-cell, cell-matrix contacts, distur-
bances of cell polarity etc. Another way of intercellular interaction involves mutual influence via paracrine fac-
tors produced by corresponding cells. However, there is another kind of information exchange between the cells,
namely microvesicular transportation. It was revealed that the exosomes take part in intercellular communication
in normal tissues as well as in malignant neoplasia. The present review provides the recent information on the
formation of exosomes, their composition and especially the exosome participation in tumor-stromal interactions.
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Introduction. The tumor development is a complex mul-
tistage process that is extremely dependent on intensive
bidirectional communication between the cancer cells
and their microenvironment. Stroma has generally been
considered as one of the major regulators of epithelial
homeostasis, and at the early stages of malignant trans-
formation it displays a capability to inhibit or even re-
verse the growth of the transformed cells [1]. However,
the further development of a tumor leads to complex al-
terations in its microenvironment, loss of its ability to
support normal epithelial architecture and function, and
emergence of tumor-promoting characteristics [2]. Such
alterations are not restricted to the primary tumor sites;
they are also shown to be an important component of the
successful metastasis establishment. Fibroblasts, that
represent the major cellular component of the epithelial
stroma, act as a leading force of these tumor-associated
changes [3, 4].
Bidirectional crosstalk between the tumor and the
surrounding stromal cells is achieved through the num-
ber of mechanisms that include the changes in chemical
and physical characteristics of intercellular matrix, di-
rect intercellular interactions and secretion of paracrine
molecules and vesicles. These vesicles convey complex
molecular messages between the tumor cells and host
organism [5]. Exosomes are recently recognized as one
of the crucial mediators of the tumor-host communica-
tion and therefore can be viewed as both a potential tar-
get and a prospective tool for anticancer therapy.
Exosomes as mediators of intercellular commu-
nication. Vesicular transport of biomolecules is a phe-
nomenon that has been observed in different species,
ranging from prokaryotes and lower eukaryotes to the
complex multicellular organisms, including mammals.
426
ISSN 0233–7657. Biopolymers and Cell. 2014. Vol. 30. N 6. P. 426–435 doi: http://dx.doi.org/10.7124/bc.0008BC
 Institute of Molecular Biology and Genetics, NAS of Ukraine, 2014
427
EXOSOMES: MESSENGERS AND MEDIATORS OF TUMOR–STROMAL INTERACTIONS
Eukaryotic cells produce several types of microvesicu-
les with distinct biochemical and functional characte-
ristics [6]. Exosomes represent a subset of secreted ex-
tracellular vesicles 30–100 nm in diameter, with charac-
teristic spherical morphology and representative biomo-
lecular composition. These characteristic features, to-
gether with the specific biogenesis pathway, serve as a
basis for distinguishing them from other types of secre-
ted vesicles [7]. According to numerous investigations,
the majority of eukaryotic cells are capable of the exo-
some production both in vivo and in vitro. This type of
vesicles can also be isolated from all the body fluids and
secretes, including blood and lymph, amniotic, broncho-
alveolar lavage and cerebrospinal fluids, saliva, urine and
breast milk, as well as from the conditioned cell culture
media.
Exosome composition. Exosomes produced by dif-
ferent cell types display significant variability in their
macromolecular composition, that can also change due
to the physiological state and age of the donor cell, as
well as in response to certain internal and external fac-
tors [7]. Additionally, it has been suggested that a sing-
le cell could possibly produce several distinct subpopu-
lations of exosomes with different macromolecular con-
tent and functions [8].
Lipidomic studies reveal a rather conservative lipid
composition of exosomal membrane and its enrichment
in lipid raft domains, saturated phospholipids and chole-
sterol, as well as in some other lipid types, that ensure
its additional stiffness and stability [9, 10]. Exosomes,
produced by the certain types of immune cells, have
been shown to contain prostaglandins and leukotriens
together with enzymes involved in their biogenesis, that
suggests their possible involvement in certain immune
reactions [11].
Extensive proteomic analysis of exosomes reveals
the presence of a wide variety of membrane-associated
and cytoplasmic proteins, typical for the cell of origin.
The most common components of exosomal membrane
are tetraspanins (CD9, CD63, CD81 and CD82) – small
tetradomain transmembrane proteins that are thought to
participate in biogenesis and specific internalization of
exosomes [12]. Additionally, the exosomal membrane
contains the components of antigen presentation system
(major histocompatibility complex, MHCI and MHCII),
multiple adhesion molecules, integrins and receptors,
including receptor tyrosine kinases and G-protein coup-
led receptors (GPCRs), components of wingless-related
integration site (Wnt) and Notch signaling pathways.
The internal lumen of these vesicles contains the proteins
involved in the exosomal biogenesis, such as annexin,
Tsg101, Rab27, Alix and syntenin-1, heat shock proteins
(HSP) and shaperones (HSP60, HSP70 and HSP90),
cytoskeletal proteins, metabolic enzymes and signaling
pathways components [9]. Although a large part of the
exosomal proteins is rather conservative due the mecha-
nisms of their biogenesis and functional properties, the
proteome also reflects the key molecular features of the
cell of origin, defined by its tissue type and functional
characteristics.
The exosomal membrane carries a conservative set
of glycoproteins involved into intercellular adhesion
and specific interactions of these vesicles with the reci-
pient cells. The glycoprotein signature of exosomes is
poorly investigated, but resent studies show the presen-
ce of polylactosamines, syaloglycoproteins and comp-
lex branched N- [13]. High rate of the exosomal surface
glycosylation leads to the suggestion that glycoproteins
may possibly participate in specific sorting of surface
molecules into exosomes [13, 14].
The discovery of exosomal RNA and, later, DNA, led
to a revision of the traditional understanding of inter-
cellular communication and emergence of a concept of
exosomal «shuttle» of nucleic acids [15]. Subsequent in-
vestigations demonstrate that exosomes contain a large
amount of functional mRNAs and microRNAs, as well
as a significant amount of tRNA, vault RNAs and other
non-coding RNA species [8, 15]. It also has been shown
that after uptake the exosomal mRNAs can be effecti-
vely translated and are able to cause metabolic changes
and epigenetic reprogramming of the recipient cells [16].
The recent data confirm also the presence of double-
strand fragments of nuclear and mitochondrial DNA, re-
trotransposones and amplified oncogene sequences in
exosomes; though, the potential function of such exoso-
mal DNA remains to be uncovered [17–19].
Exosome biogenesis. A specific mechanism of bio-
genesis is a characteristic feature of exosomes that cle-
arly distinguishes them from other types of secreted
microvesicles. The initial formation of late endosomes
(also termed as multivesicular bodies) is a result of in-
ward budding of primary endosome membrane, that
causes the formation of multiple intraluminal vesicles.
This process is generally mediated by Endosomal Com-
plex Required for Transport (ESCRT) and additional
proteins, involved in multivesicular body transport, do-
cking and fusion with the cellular membrane [8]. Fu-
sion of the late endosomes with the outer cellular memb-
rane is a well-described phenomenon that results in the
release of the vesicles that are now termed as exosomes
(Figure). However, there is an experimental evidence de-
monstrating that the formation of multivesicular bodies
can also proceed independently from ESCRT, sugges-
ting the existence of alternative mechanisms of their bio-
genesis[20].
The difference in molecular composition of the exo-
somes and the cellular cytoplasm suggest a possible exi-
stence of the specific sorting mechanisms of their com-
ponents [8]. It has been shown that the targeting of pro-
teins into exosomes does not require any special sequ-
ences, but often involves certain post-translational mo-
difications, such as ubiquitinilation and SUMOylation,
as well as phosphorylation and glycosylation of parti-
cular amino acid residues [21]. Other proposed mecha-
nisms involve the membrane protein oligomerisation,
and their inclusion into lipid rafts and tetraspanin-rich
domains [12, 22]. The mechanisms of RNA targeting are
also poorly understood. Several recent experiments have
indicated that RNA sorting requires the presence of spe-
cific sequences (25-nucleotide «Zip-codes» for mRNA
and special motifs in miRNA) in their composition and
is realized through the interactions with several types of
heterogenic nuclear ribonucleoproteins and miRNAs
[8, 23, 24]. Some miRNAs may interact with the com-
ponents of ESCRT and, therefore, be sorted into multi-
vesicular bodies for lysosomal degradation or extracel-
lular release [25]. One of the recent studies provides the
evidence that miRNA sorting might be modulated by the
internal target RNA concentration, therefore serving al-
so as the possible way of regulating intracellular RNA
homeostasis [26].
However, the exact mechanisms underlying the spe-
cific sorting of exosomal content, remain a subject for
future investigations.
Secretion of exosomes can proceed in a constitutive
or a stimuli-dependent manner. Its rate depends on the
number of factors and can vary according to the physio-
logical state of the donor cell, cell cycle stage, cellular
senescence, and in response to the stress and external
stimulation [27, 28]. Such external stimuli include chan-
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ges in macromolecular and physico-mechanic proper-
ties of extracellular matrix, a significant decrease in ex-
tracellular pH, hypoxia, membrane depolarization (for
the certain cell types), treatment of the cell with ATP,
cytokines and growth factors, etc. [29].
Interaction with the recipient cells. Exosomes act as
mediators of intercellular communication by transpor-
ting a variety of internal and surface-associated mole-
cules and ligands. In extracellular space, they are recog-
nized and captured by different types of cells. This abili-
ty of exosomes to be specifically recognized and proces-
sed by the cells depends on specific sialiglycoproteins
and proteoglycans, adhesion molecules, integrins and
tetraspanins in different combinations, which are pre-
sent on the exosomal surface [12, 14].
The interaction of exosomes with the recipient cells
can proceed in several ways (Figure). Some types of li-
gands, associated with the exosomal surface, can be re-
cognized by cellular transmembrane receptors [30]. Se-
veral experiments suggest the possibility of direct fu-
sion of the exosomal membrane with the outer cellular
membrane; however, this process requires the match in
fluidity of both participating membranes and therefore
is restricted primarily to low pH conditions, such as tho-
se observed in the hypoxic solid tumors [31].
The mechanisms of exosome internalization are
shown to be cell-type dependent and can proceed through
phagocytosis, macropinocytosis or multiple types of en-
docytosis, including clathrin-, caveolin- and dynamin-
dependent mechanisms [8]. The further fate of interna-
lized exosomes is poorly investigated; according to the
recent data, they can be transported to the lysosomal
compartment, where their membrane undergoes degra-
dation [32]. Other investigations demonstrate that exo-
somes can also accumulate inside multivesicular bo-
dies of the recipient cell, suggesting the dual role of the-
se organelles in exosomal metabolism [10].
The pleiotropic effect of exosomes is mediated by a
wide range of signaling molecules, enzymes and dif-
ferent kinds of functional nucleic acids that can alter the
cellular metabolism and gene expression pattern of the
recipient cell. Upon exosome internalization and pro-
cessing, active forms of signaling molecules and enzy-
mes can be involved into a variety of intracellular pro-
cesses. Furthermore, recent investigations have revea-
led an important role of exosomal mRNAs and micro
RNAs in wide post-transcriptional regulation of the ge-
ne expression in recipient cells [16][33].
Function of exosomes in normal and pathologi-
cal conditions. According to the predominant concep-
tion of early investigations, exosomes served as a cellu-
lar «waste bin» and functioned mainly to remove obso-
lete and defective protein molecules from the cell [34].
However, the extensive investigations of the exosome
structure and function, conducted during the last 15
years, shed the light on their participation in many phy-
siological and pathological processes, which depends
on the intercellular communication and signaling.
This type of microvesicles is produced by the majo-
rity of immune cells, including dendritic cells, T- and B-
lymphocytes, eosinophils, macrophages and mast cells.
In the immune system, they are involved in antigen pre-
sentation and immune synapse establishment, immune
response regulation, negative selection of T-cells in thy-
mus and regulatory T-cells formation [35]. Cytotoxic T-
lymphocytes are shown to produce the exosomes carry-
ing certain cell death-initiating molecules, particularly
Fas ligand and Tumor Necrosis Factor-related apopto-
sis-inducing ligand (TRAIL) on their membranes. Af-
ter uptake, these exosomes are capable of initiating pro-
grammed death of transformed cells, thus conducting
anti-tumor immune defense [36]. In nervous system,
exosomes are produced by both neurons and different
types of glia and participate in regulation of the central
nervous system development, neuro-glial communica-
tion and glia differentiation, synaptic activity of neurons
[37]. Some data show that they might have neuroprotec-
tive and pro-regeneratory activity [38, 39]. In reproduc-
tive system, exosomes are apparently involved in regu-
lation of certain aspects of gametogenesis, fertilization
and implantation, as well as in establishment of dense
interactions between a fetus and a mother organism
[40–42].
Progression of many diseases is associated with the
alterations in intercellular communication system, lea-
ding to the general perturbation of organism homeosta-
sis. Exosomes are shown to be important players in in-
flammation, development of some cardiovascular disea-
ses, hypercholesterinemia, diabetes and obesity, and neu-
rodegenerative conditions, including multiple sclerosis
development, Alzgeimer’s and Parkinson’s diseases
[43–45]. Pathogenesis of several infectious diseases, cau-
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sed by some viruses, mycobacteria and protozoa, also de-
pends on the exosome secretion [46]. A role of exosomes
in this case can be either pro-immunogenic or immune-
suppressive, depending on the nature of pathogen [35].
For example, the macrophages, infected with non-pa-
thogenic strain of mycobacteria, release exosomes bea-
ring bacterial antigens and promoting immune respon-
se; at the same time, exosomes, associated with the pa-
thogenic strain infection, inhibit macrophage activation
and cytokine secretion, thus diminishing immune res-
ponse [47, 48]. Some human viruses, including HIV and
Epstein-Barr virus (EVB), utilize exosomal pathway
for spreading among the cells and immune evasion [49,
50].
For example, the cells infected with EBV, release
exosomes, containing some signaling and viral proteins
and miRNA [51, 52]. Following the intake, these exoso-
mes can activate the mitogen-activated protein kinase
(MAPK) and PI3K/Akt signaling pathways, leading to
increased proliferation of recipient cells, associated with
the oncogenic effect of the virus [52].
Several studies revealed also unexpected function of
exosomes in spreading prion proteins, thus participating
in the progression of the prion-associated neurodegene-
rative processes [53].
Exosomes in oncogenesis. The establishment and
progression of a malignant tumor are extremely depen-
dent on its interactions with surrounding tissues, as well
as on its ability to influence distant tissues and organs
[54]. According to the data accumulated during the last
1.5 decades of research, exosomes are shown to play an
important role in all the stages of oncogenesis. They par-
ticipate in regulation of antitumor immunity, angioge-
nesis, tumor–stroma interactions, invasion and premeta-
static niche formation [55].
Exosomes in tumormicroenvironment regulation. In
tumor microenvironment, exosomes are actively produ-
ced by both normal and malignant cells and participate
in establishment of complex regulatory networks bet-
ween tumor and the adjacent tissues. Malignant cells re-
lease higher amounts of exosomes than non-malignant
cells; the quantity of exosomes produced by the cell di-
rectly correlates with the rate of its aggressiveness [56].
Following the release into extracellular environ-
ment, exosomes either interact with the same cell in au-
tocrine manner or can be captured and internalized by
the adjacent malignant and non-malignant cells. Exoso-
mal exchange inside the malignant cell population can
inhibit pro-apoptotic signaling and stimulate prolifera-
tion through PI3K/Akt and MAPK/ERK signaling path-
ways [57]. Exchange of proteins and RNA between dif-
ferent subpopulations of tumor cells has also been recog-
nized as an important factor in transfer of malignant phe-
notypic features from more aggressive cells to less ag-
gressive [58]. This kind of communication accounts for
extracellular exchange of oncogenic proteins. For exam-
ple, such transfer of mutant form of epidermal growth
factor receptor (EGFRvIII) to the cells previously la-
cking it leads to initiation of anti-apoptotic protein ex-
pression and increased proliferation [59]. Similar me-
chanisms are employed in the exchange of mutant forms
of K-RAS protein in colon carcinoma cells [11]. Some
cancer cells secrete exosomes with high quantities of
survavin, an apoptosis inhibitor, and therefore facilitate
the survival of other cells in population [60].
It has been suggested that exosomes play a crucial
role in establishing and spreading chemoresistance insi-
de the tumor cell population. Some anticancer drugs ha-
ve been shown to affect the rate of extracellular vesicle
release. Several chemotherapeutic drugs, such as cispla-
tin and doxorubicin, can be actively released from the
cell through the incorporation into exosomes [61, 62].
Strikingly, some kinds of chemoresistance are the sub-
ject for intercellular transfer. For example, the exoso-
mes, released from the drug-resistant cancer cells, can
transfer a multidrug transporter P-glycoprotein to the
drug-sensitive cells [63]. The same mechanisms of acti-
ve export are also described for some important anti-
apoptotic regulators, including PTEN [64].
Exosomes as regulators of aggressive behavior of
cancer cells. Hypoxia is one of the common features of
solid tumor microenvironment. According to several
experiments, it leads to the stimulation of production of
increased quantities of the tumor cell exosomes, that, in
turn, are capable of stimulation of angiogenesis and in-
vasiveness [65, 66]. A decrease of extracellular pH, asso-
ciated with the low oxygen concentration, also favors an
active intake of exosomes by surrounding transformed
cells and stroma [65]. Microvesicles, produced by the
hypoxic cancer cells, contain the increased amounts of
cytokines, growth factors and certain types of miRNAs,
as well as surface-associated ligands, that together sti-
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mulate the pro-angiogenic response inside surrounding
tissue [67]. For example, incorporation of vesicles with
VEGF by endoteliocytes leads to the activation of Akt
and MAPK pathways and expression of VEGFR [68].
The colon cancer derived exosomes contain the mRNA
of cell cycle regulators that after intake in endotelio-
cytes and translation significantly stimulate their proli-
feration [69]. Other exosomal ligands, such as Delta-
like-4, inhibit division of endoteliocytes in vitro, but at
the same time increase their migratory activity [70].
Taken altogether, these findings suggest for the major
pro-angiogenic functions of tumor exosomes.
One of the most dangerous features of the malignant
behavior of cancer cells is their invasiveness, or ability
to penetrate the basal membrane barriers and invade in-
to surrounding tissues. The proteolysis-dependent inva-
sion requires the formation of invadopodia – three-di-
mensional membrane protrusions that participate in de-
gradation of extracellular matrix components and facili-
tate cancer cell migration into surrounding stroma. Re-
sent investigation shows that ability of the cancer cell
to generate invadopodia displays direct correlation with
the rate of exosomal secretion. Invadopodia contain the
multiple multivesicular bodies docking sites that promo-
te the exosome release into extracellular environment.
The release of exosomes, in turn, triggers the formation
of new invadopodia, thus establishing a positive feed-
back loop [56].
Highly invasive cells also produce the exosomes en-
riched in membrane-associated forms of the matrix me-
talloproteinases, such as MMP2, MMP9 and urokinase
plasminogen activator, as well as in HSP, particularly
HSP90, that can also activate the extracellular endopep-
tidases, therefore facilitating the matrix degradation [71,
72].
Tumor exosomes in immunity modulation. Tumor
cell exosomes have been shown to interact with immu-
ne system, causing both pro-immunogenic and anti-im-
munogenic effects. Under normal conditions, they are
recognized and processed by the different types of anti-
gen-presenting cells, and trigger antitumor immunity.
However, this mechanism can be hijacked by tumor cells.
The malignant cells are shown to produce exosomes
with altered functions and composition, that instead of
triggering a cytotoxic immune response modulate and
suppress antitumor immunity. For example, they can
impede the activation of dendritic and T-cells and initi-
ate the suppressor and regulatory T-cell generation. Re-
gulatory T-cells, in turn, suppress cytotoxic T-cells that
normally conduct a anti-tumor response [73] [74]. The
exosomes carrying Faso can also directly induce apop-
tosis of the CD8-positive T-cell [74].
Exosomes in tumor–stroma interactions. The tumor–
stroma interactions are currently recognized as an im-
portant factor in ontogenesis progression that signifi-
cantly affect the tumor cells signaling, survival and pro-
liferation, as well as modulate their invasive properties
and drug sensitivity. Certain primary alterations in tu-
mor stroma may lead to an increased risk of the tumor
development [75]. For example, a loss of PTEN expres-
sion in stromal fibroblasts is associated with a higher
risk of the breast tumor development. At the same time,
the normal expression of this gene is necessary for the
maintenance of normal epithelial homeostasis [76].
Bidirectional communication between stroma and
cancer cells is achieved through a number of mecha-
nisms, such as establishment of direct intercellular junc-
tions and extracellular matrix alterations, as well as by
secretion of some paracrine ligands and microvesicles.
Numerous investigations confirm the fact that the ex-
change of exosomes between malignant and stromal
cells takes place both in vitro and in vivo [77]. Some of
the well-recognized mediators of tumor–stroma com-
munication, such as transforming growth factor  (TGF
) and members of Wnt family, are present in tumor mic-
roenvironment in both soluble form and in association
with the outer exosomal membrane [78, 79].
TGF is one of the most recognized factors involved
in tumor to stroma signaling and fibroblast activation.
During the normal wound healing process, epithelial
cells produce TGF1-containing exosomes, that are ab-
le to activate adjacent stromal fibroblasts, thus creating
favorable conditions for epithelial regeneration [80].
The activation of carcinoma-associated fibroblasts
(CAFs) is a representative feature of tumor stroma, and
is underlain by the same mechanisms. According to the
literature data, the exosomes bearing TGF can cause an
activation of normal fibroblasts, as well as initiate the
differentiation of mesenchymal stem cells and adipo-
cytes into myofibroblast-like cells [78, 81–83]. Certain
research findings support the conclusion that the vesi-
cular rather than the soluble form of TGF1 has pro-on-
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cogenic activating effect on fibroblasts. Such effect is
possibly mediated by additional ligands on the surface
of exosomes, particularly by the heparansulphate chains
that can significantly affect the internal signal transduc-
tion pathways [78].
The activated fibroblasts at the tumor growth sites
carry out numerous tumor-supportive activities, secre-
ting large quantities of growth factors and cytokines,
participating in external matrix proteolysis and remode-
ling, recruiting endotheliocytes, macrophages and me-
senchymal stem cells [4]. Among other factors, they pro-
duce large quantities of exosome-anchored Wnt, that
normally serves as an important mediator of cell polari-
ty and locomotion in embryogenesis and in adult tissues
[84]. During the tumor development, Wnt acts as a posi-
tive regulator of locomotion activity and invasiveness
of malignant cells. According to the recent data, the exo-
somes bearing a membrane-anchored form of Wnt acti-
vate the planar cell polarity (PCP) pathway in the breast
cancer cells and increase their motility, and therefore
promote the invasion and metastasis [85]. Taken toge-
ther, these findings reveal a previously unknown me-
chanism of the tumor-stroma interactions via exosomes
and point on the crucial role these vesicles may play in
the tumor establishment and progression. However, the
exact nature and mechanisms underlying this phenome-
non remains the subject for further investigations.
Clinical significance of tumor-derived exosomes.
Macromolecular composition of exosomes closely mi-
mics the key molecular features of the donor cell, and
therefore can serve as a potential source of information
about its physiological state and the gene expression pro-
file. Tumor cells secrete increased amount of extracel-
lular vesicles, comparing to non-malignant cells, and
these vesicles can be identified in the majority of bio-
logical fluids, laying the basis for new diagnostic strate-
gies. Tumor exosomes contain large quantities of tumor-
specific proteins and nucleic acids. Some miRNAs are
specifically expressed in transformed cells and can be
found in their exosomes [86]. Since they do not under-
go extracellular nuclease degradation, these RNAs can
be detected during the long period and in relatively low
concentrations. This seems especially valuable in case
of malignancies that usually difficult to identify during
the early stages of their development [7]. Exosomes may
also be used for determination of the most efficient com-
bination of drugs and assessment of therapeutic effect
in the course of treatment [87].
Due to their important role in oncogenesis, exoso-
mes are seriously considered as a potential target for no-
vel anti-tumor therapies [88]. For example, in experi-
ments the inhibition of exosome secretion can suppress
the cancer cell proliferation and metastatic capabilities;
but the real clinical value of such inhibitors is rather un-
clear. Another proposed therapeutic approach for advan-
ced-stage cancer treatment implies the total clearance
of the patient's blood from all the exosomes with HER2
antibodies [89]. Some strategies require therapeutic blo-
ckage of the exosome production by malignant and host
cells by targeting exosome biogenesis pathway, or pre-
venting their uptake by recipient cells.
Ubiquitousness and physiological relevance of exo-
somes make them a promising next-generation drug de-
livery system for targeted therapy of cancer [90]. They
may be implied as the vectors for a specific transport of
certain proteins, oncosupressor mRNAs and miRNAs,
as well as artificial chemotherapeutic compounds [91,
92]. The major advantages of exosomes, comparing to
other vector systems, are their non-imunogenic proper-
ties, high stability under physiological conditions, and
existence of the natural mechanisms of specific recog-
nition and internalization [93]. This makes them an at-
tractive tool for developing the field of RNA medicine,
where the creation of effective delivery system is one of
the major problems [94]. However, though there is a
growing number of proposed implications of exosomes
in clinical oncology, they remain primarily theoretic,
and there is currently no approved treatment strategy or
diagnostic tools employing this type of vesicles. Further
investigations are required to ensure safe and effective
application of exosomes for the cancer therapy.
Conclusions. The emerging conception of intercel-
lular vesicular transport of biomolecules challenges the
traditional understanding of mechanism of intercellular
communication in eukaryotic organisms. The recent ad-
vances in exosome research shed light on the signifi-
cant role of this type of secreted microvesicles in a wide
range of physiological and pathological processes. How-
ever, the exact nature of the mechanisms of exosome
production and interactions with the recipient cells, as
well as many of their functions in norma and patholo-
gy, still remain rather unclear. A detailed investigation
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of exosomes, as well as other microvesicles and media-
tors, in cancer, and tumor-stroma communications in
particular, might bring a new understanding of mecha-
nisms that underlie malignant transformation and tumor
progression, and lead to optimization of current oncolo-
gical diagnostic and therapeutic methods.
Åêçîñîìè ÿê ïîñåðåäíèêè ïóõëèíî-ñòðîìàëüíèõ âçàºìîä³é
Øêàð³íà Ê. À., ×åðåäíèê Î. Â., Âîëîùåíêî ². ²., Òðåìáà÷ Î. Ì.,
Òðåìáà÷ ². Î., Õîðóæåíêî À. ².
Ðåçþìå
Ì³æêë³òèíí³ êîìóí³êàö³¿ º îäíèì ç íàéâàæëèâ³øèõ ôàêòîð³â, ÿê³
áåðóòü ó÷àñòü ó ï³äòðèìö³ òêàíèííîãî ãîìåîñòàçó. Ïîðóøåííÿ
ì³æêë³òèííèõ âçàºìîä³é êîðåëþº ç âåëèêîþ ê³ëüê³ñòþ çàõâîðþ-
âàíü, ñåðåä ÿêèõ êàíöåðîãåíåç. ²ñíóº ê³ëüêà òèï³â ì³æêë³òèííèõ
âçàºìîä³é. Íàñàìïåðåä, öå áåçïîñåðåäí³é êîíòàêò êë³òèíà–êë³-
òèíà, ùî õàðàêòåðíî äëÿ åï³òåë³ÿ. Çá³é òàêî¿ ì³æêë³òèííî¿ âçàº-
ìîä³¿ ìàº íàñë³äêîì âòðàòó ì³æêë³òèííèõ êîíòàêò³â, êîíòàê-
ò³â êë³òèíà–ìàòðèêñ, ïîðóøåííÿ êë³òèííî¿ ïîëÿðíîñò³ ³ ò. ä. ²í-
øèé ñïîñ³á ì³æêë³òèííî¿ âçàºìîä³¿ ïîëÿãàº ó âçàºìíîìó âïëèâîâ³,
îïîñåðåäêîâàíîìó ïàðàêðèííèìè ÷èííèêàìè, ÿê³ ïðîäóêóþòüñÿ
â³äïîâ³äíèìè êë³òèíàìè. Îäíàê º ùå îäèí òèï îáì³íó ³íôîðìàö³-
ºþ ì³æ êë³òèíàìè, à ñàìå – ì³êðîâåçèêóëÿðíèé òðàíñïîðò. Âñòà-
íîâëåíî, ùî ì³êðîâåçèêóëè åêçîñîì áåðóòü ó÷àñòü ó âçàºìîä³¿ êë³-
òèí ó íîðìàëüíèõ òêàíèíàõ, à òàêîæ ó çëîÿê³ñíèõ íîâîóòâîðåí-
íÿõ. Ïðåäñòàâëåíèé îãëÿä íàäàº ñó÷àñíó ³íôîðìàö³þ ùîäî ôîð-
ìóâàííÿ åêçîñîì, ¿õíüîãî ñêëàäó ³, îñîáëèâî, ¿õíüî¿ ïðè÷åòíîñò³ äî
ïóõëèíî-ñòðîìàëüíèõ âçàºìîä³é.
Êëþ÷îâ³ ñëîâà: åêçîñîìè, ïóõëèíî-ñòðîìàëüíà âçàºìîä³ÿ.
Ýêçîñîìû êàê ïîñðåäíèêè îïóõîëåâî-ñòðîìàëüíûõ
âçàèìîäåéñòâèé
Øêàðèíà Å. À., ×åðåäíèê Î. Â., Âîëîùåíêî È. È., Òðåìáà÷ À. Ì.,
Òðåìáà÷ È. À., Õîðóæåíêî À. È.
Ðåçþìå
Ìåæêëåòî÷íûå êîììóíèêàöèè ÿâëÿþòñÿ îäíèì èç íàèáîëåå âàæ-
íûõ ôàêòîðîâ, ó÷àñòâóþùèõ â ïîääåðæàíèè òêàíåâîãî ãîìåîñ-
òàçà. Íàðóøåíèå ìåæêëåòî÷íûõ âçàèìîäåéñòâèé êîððåëèðóåò ñ
áîëüøèì êîëè÷åñòâîì çàáîëåâàíèé, âêëþ÷àÿ êàíöåðîãåíåç. Ñóùå-
ñòâóåò íåñêîëüêî òèïîâ ìåæêëåòî÷íûõ âçàèìîäåéñòâèé. Ïðåæ-
äå âñåãî, ýòî íåïîñðåäñòâåííûé êîíòàêò êëåòêà–êëåòêà, ÷òî õà-
ðàêòåðíî äëÿ ýïèòåëèÿ. Ñáîé òàêîãî ìåæêëåòî÷íîãî âçàèìîäåé-
ñòâèÿ âûðàæàåòñÿ â ïîòåðå ìåæêëåòî÷íûõ êîíòàêòîâ, êîíòàê-
òîâ êëåòêà–ìàòðèêñ, â íàðóøåíèè êëåòî÷íîé ïîëÿðíîñòè è ò. ä.
Äðóãîé ñïîñîá ìåæêëåòî÷íîãî âçàèìîäåéñòâèÿ çàêëþ÷àåòñÿ âî
âçàèìîâëèÿíèè, îïîñðåäîâàííîì ïàðàêðèííûìè ôàêòîðàìè, ïðî-
äóöèðóåìûìè ñîîòâåòñòâóþùèìè êëåòêàìè. Îäíàêî ñóùåñòâó-
åò åùå îäèí òèï îáìåíà èíôîðìàöèåé ìåæäó êëåòêàìè, à èìåí-
íî – ìèêðîâåçèêóëÿðíûé òðàíñïîðò. Óñòàíîâëåíî, ÷òî ìèêðîâå-
çèêóëû ýêçîñîì ó÷àñòâóþò âî âçàèìîäåéñòâèè êëåòîê â íîðìàëü-
íûõ òêàíÿõ, à òàêæå â çëîêà÷åñòâåííûõ íîâîîáðàçîâàíèÿõ. Íà-
ñòîÿùèé îáçîð ïðåäîñòàâëÿåò ñîâðåìåííóþ èíôîðìàöèþ î ôîð-
ìèðîâàíèè ýêçîñîì, èõ ñîñòàâå è, îñîáåííî, îá èõ ïðè÷àñòíîñòè ê
îïóõîëåâî-ñòðîìàëüíûì âçàèìîäåéñòâèÿì.
Êëþ÷åâûå ñëîâà: ýêçîñîìû, îïóõîëåâî-ñòðîìàëüíîå âçàèìî-
äåéñòâèå.
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